JAK Inhibitors: Updated Safety Signals, Patient Selection and Post-ORAL Surveillance

This on-demand webinar is a recorded episode from the Drug Class Explainers series.
Listen to the full session below and earn 0.5 CPD hours upon completion.

JAK inhibitors have transformed inflammatory diseases from rheumatoid arthritis to eczema — but post-marketing safety data has reshaped how we use them. Dr Anzal Qurbain unpacks the updated MHRA and EMA guidance on cardiovascular and malignancy risk, and how to select the right patient for these oral targeted therapies.